Crossmark

Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy

Crossref DOI link: https://doi.org/10.1186/s12967-019-1984-2

Published Online: 2019-07-23

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Onesti, Concetta Elisa

Boemer, François

Josse, Claire https://orcid.org/0000-0003-0315-3718
Leduc, Stephane

Bours, Vincent

Jerusalem, Guy
Funding

Funding for this research was provided by:

Belgian Fund for Scientific Research

Fondation contre le cancer

FIRS CHU Liege

Fonds Léon Fredericq
License Information

Text and Data Mining valid from 2019-07-23

Version of Record valid from 2019-07-23
More Information

Article History

Received: 16 May 2019

Accepted: 17 July 2019

First Online: 23 July 2019

Ethics approval and consent to participate

: This study was conducted in accordance with the Declaration of Helsinki. The institutional ethics committee of the University Hospital of Liège (Belgium) approved the protocols under the following committee’s reference numbers: 2010/252; 2013/214 and 2013/215.

: Each patient or healthy control signed informed consent before inclusion in the trial, including acceptance for data publication.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below